Literature DB >> 19752287

Autoimmune targets of heart and skeletal muscles in myasthenia gravis.

Shigeaki Suzuki1, Kimiaki Utsugisawa, Hiroaki Yoshikawa, Masakatsu Motomura, Shiro Matsubara, Kazumasa Yokoyama, Yuriko Nagane, Takahiro Maruta, Takashi Satoh, Hideki Sato, Masataka Kuwana, Norihiro Suzuki.   

Abstract

OBJECTIVE: To investigate the clinical, histological, and immunological features of patients with myasthenia gravis (MG) who also developed myocarditis and/or myositis.
DESIGN: Observational and retrospective case series.
SETTING: Keio University, Hanamaki General Hospital, Kanazawa University, Nagasaki University, and Juntendo University. PATIENTS: A cohort of 8 patients with MG with clinically defined inflammatory myopathies.
INTERVENTIONS: Clinical and histological features were described. Serological analyses included MG-related antistriational autoantibodies (those to titin, ryanodine receptor, muscular voltage-gated potassium channel Kv1.4) and myositis-specific autoantibodies.
RESULTS: Of 924 patients with MG, 8 (0.9%) had inflammatory myopathies. The mean (SD) onset age of MG was 55.3 (10.3) years. All patients showed severe symptoms with bulbar involvement; 5 patients had myasthenic crisis and 4 had invasive thymoma. Myocarditis was found in 3 patients and myositis in 6. Myocarditis, developing 13 to 211 months after the MG onset, was characterized by heart failure and arrhythmias. Myositis, developing before or at the same time as MG, affected limb and paraspinal muscles. Histological findings of skeletal muscles showed CD8(+) lymphocyte infiltration. Seven patients had 1 of these antistriational autoantibodies but not myositis-specific autoantibodies. Immunomodulatory therapy was required for all patients and was effective for both MG and inflammatory myopathies, although 1 patient died.
CONCLUSIONS: Heart and skeletal muscles are autoimmune targets in some patients with MG. This autoimmunity has a broad clinical spectrum with antistriational autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752287     DOI: 10.1001/archneurol.2009.229

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  43 in total

Review 1.  Paraneoplastic disorders in thymoma patients.

Authors:  Amelia Evoli; Eric Lancaster
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

2.  Subacute progressive ophthalmoplegia associated with dermatomyositis.

Authors:  Satoshi Kono; Tomoyasu Bunai; Tatsuhiro Terada; Kumiko Shimoyama; Takashi Konishi; Kentaro Shirakawa; Hiroaki Miyajima
Journal:  J Neurol       Date:  2012-04-20       Impact factor: 4.849

Review 3.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

4.  A case of myasthenia gravis with cardiac fibrosis and easily provoked sustained ventricular tachycardia.

Authors:  Aiko Sakamoto; Miyuki Yamamoto; Masao Takahashi; Kohsuke Ajiki; Satoshi Ota; Akimichi Murakami; Makoto Mutou; Kamon Imai; Takahiro Maruta; Hiroaki Yoshikawa; Nobukazu Ishizaka; Hiroshi Yamashita; Yasunobu Hirata; Ryozo Nagai
Journal:  J Cardiol Cases       Date:  2010-02-19

Review 5.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

6.  Non-coronary myocardial infarction in myasthenia gravis: Case report and review of the literature.

Authors:  Panagiotis Zis; Stavros Dimopoulos; Vasiliki Markaki; Antonios Tavernarakis; Serafim Nanas
Journal:  World J Cardiol       Date:  2013-07-26

7.  Vaccination mitigates influenza-induced muscular declines in aged mice.

Authors:  Spencer R Keilich; Erica C Lorenzo; Blake L Torrance; Andrew G Harrison; Jenna M Bartley; Laura Haynes
Journal:  Geroscience       Date:  2020-05-29       Impact factor: 7.713

Review 8.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

Review 9.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 10.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.